Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Draft as of 2026-07-13 |
<ConceptMap xmlns="http://hl7.org/fhir">
<id value="dhis-observation-component-to-loinc"/>
<language value="en"/>
<text>
<status value="generated"/>
<div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: ConceptMap dhis-observation-component-to-loinc</b></p><a name="dhis-observation-component-to-loinc"> </a><a name="hcdhis-observation-component-to-loinc"> </a><p>Mapping from (not specified) to <a href="http://loinc.org/">All LOINC codes</a></p><br/><p>Mapping from <a href="CodeSystem-dhis-observation-component-code-cs.html">DHIS Observation Component Code CodeSystemversion: 0.1.0)</a> to <code>http://loinc.org</code> (Logical Observation Identifier Names and Codes (LOINC))</p><table class="grid"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td></tr><tr><td>tub004-0007 (Rifampitsin (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>18974-6 (Rifampin [Susceptibility])</td></tr><tr><td>tub004-0008 (Izoniazid (0,1 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>18934-0 (Isoniazid [Susceptibility])</td></tr><tr><td>tub004-0009 (Etambutol (5,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>18921-7 (Ethambutol [Susceptibility])</td></tr><tr><td>tub004-0010 (Pirazinamid (100 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>18973-8 (Pyrazinamide [Susceptibility])</td></tr><tr><td>tub004-0011 (Levofloksatsin (2,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>20629-2 (Levofloxacin [Susceptibility])</td></tr><tr><td>tub004-0012 (Moksifloksatsin (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>31039-1 (Moxifloxacin [Susceptibility])</td></tr><tr><td>tub004-0013 (Moksifloksatsin (0,25 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>31039-1 (Moxifloxacin [Susceptibility])</td></tr><tr><td>tub004-0014 (Gatifloksatsin (0,25 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>31038-3 (Gatifloxacin [Susceptibility])</td></tr><tr><td>tub004-0015 (Amikatsin (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>18860-7 (Amikacin [Susceptibility])</td></tr><tr><td>tub004-0016 (Protionamid (2,5 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>100057-9 (Prothionamide [Susceptibility])</td></tr><tr><td>tub004-0017 (Linezolid (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>29258-1 (Linezolid [Susceptibility])</td></tr><tr><td>tub004-0018 (Klofazimin (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>23627-3 (Clofazimine [Susceptibility])</td></tr><tr><td>tub004-0019 (Bedaquilin (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>94274-8 (Bedaquiline [Susceptibility])</td></tr><tr><td>tub004-0020 (Delamanid (0,06 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>93851-4 (Delamanid [Susceptibility])</td></tr><tr><td>tub004-0021 (Pretomanid (1,0 mg/ml))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target" title="source-is-narrower-than-target">is narrower than</a></td><td>93850-6 (Pretomanid [Susceptibility])</td></tr><tr><td>tub004-0025 (Ethionamide-Prothionamide)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#related-to" title="related-to">is related to</a></td><td>18922-5 (Ethionamide [Susceptibility])</td></tr><tr><td>tub004-0022 (Rifampcin)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>18974-6 (Rifampin [Susceptibility])</td></tr><tr><td>tub004-0028 (Levofloxacin)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>20629-2 (Levofloxacin [Susceptibility])</td></tr><tr><td>tub004-0029 (Amikacin)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>18860-7 (Amikacin [Susceptibility])</td></tr><tr><td>tub004-0030 (Kanamycin)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>18935-7 (Kanamycin [Susceptibility])</td></tr></table></div>
</text>
<url
value="https://terminology.dhp.uz/fhir/integrations/ConceptMap/dhis-observation-component-to-loinc"/>
<version value="0.1.0"/>
<name value="ObservationComponentToLoinc"/>
<title value="Tuberculosis Drug Susceptibility Components to LOINC"/>
<status value="draft"/>
<experimental value="false"/>
<date value="2026-07-13T16:58:44+05:00"/>
<publisher value="Uzinfocom LLC"/>
<contact>
<name value="Uzinfocom LLC"/>
<telecom>
<system value="url"/>
<value value="https://uzinfocom.uz"/>
</telecom>
<telecom>
<system value="email"/>
<value value="info@uzinfocom.uz"/>
</telecom>
</contact>
<description
value="Maps the local DHIS drug-susceptibility-test component codes to their LOINC [Susceptibility] code. Where the relationship is `equivalent` (plain drug-name agents), use the LOINC code directly in resources (see the DHIS Observation Component Code ValueSet); concentration-bearing agents are narrower and keep their local code. Non-drug component codes (interpretations, grading, identification flags) have no LOINC equivalent and are not listed."/>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="UZ"/>
<display value="Uzbekistan"/>
</coding>
</jurisdiction>
<targetScopeCanonical value="http://loinc.org/vs"/>
<group>
<source
value="https://terminology.dhp.uz/fhir/integrations/CodeSystem/dhis-observation-component-code-cs|0.1.0"/>
<target value="http://loinc.org"/>
<element>
<code value="tub004-0007"/>
<display value="Rifampitsin (1,0 mg/ml)"/>
<target>
<code value="18974-6"/>
<display value="Rifampin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0008"/>
<display value="Izoniazid (0,1 mg/ml)"/>
<target>
<code value="18934-0"/>
<display value="Isoniazid [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0009"/>
<display value="Etambutol (5,0 mg/ml)"/>
<target>
<code value="18921-7"/>
<display value="Ethambutol [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0010"/>
<display value="Pirazinamid (100 mg/ml)"/>
<target>
<code value="18973-8"/>
<display value="Pyrazinamide [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0011"/>
<display value="Levofloksatsin (2,0 mg/ml)"/>
<target>
<code value="20629-2"/>
<display value="Levofloxacin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0012"/>
<display value="Moksifloksatsin (1,0 mg/ml)"/>
<target>
<code value="31039-1"/>
<display value="Moxifloxacin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0013"/>
<display value="Moksifloksatsin (0,25 mg/ml)"/>
<target>
<code value="31039-1"/>
<display value="Moxifloxacin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0014"/>
<display value="Gatifloksatsin (0,25 mg/ml)"/>
<target>
<code value="31038-3"/>
<display value="Gatifloxacin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0015"/>
<display value="Amikatsin (1,0 mg/ml)"/>
<target>
<code value="18860-7"/>
<display value="Amikacin [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0016"/>
<display value="Protionamid (2,5 mg/ml)"/>
<target>
<code value="100057-9"/>
<display value="Prothionamide [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0017"/>
<display value="Linezolid (1,0 mg/ml)"/>
<target>
<code value="29258-1"/>
<display value="Linezolid [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0018"/>
<display value="Klofazimin (1,0 mg/ml)"/>
<target>
<code value="23627-3"/>
<display value="Clofazimine [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0019"/>
<display value="Bedaquilin (1,0 mg/ml)"/>
<target>
<code value="94274-8"/>
<display value="Bedaquiline [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0020"/>
<display value="Delamanid (0,06 mg/ml)"/>
<target>
<code value="93851-4"/>
<display value="Delamanid [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0021"/>
<display value="Pretomanid (1,0 mg/ml)"/>
<target>
<code value="93850-6"/>
<display value="Pretomanid [Susceptibility]"/>
<relationship value="source-is-narrower-than-target"/>
</target>
</element>
<element>
<code value="tub004-0025"/>
<display value="Ethionamide-Prothionamide"/>
<target>
<code value="18922-5"/>
<display value="Ethionamide [Susceptibility]"/>
<relationship value="related-to"/>
</target>
</element>
<element>
<code value="tub004-0022"/>
<display value="Rifampcin"/>
<target>
<code value="18974-6"/>
<display value="Rifampin [Susceptibility]"/>
<relationship value="equivalent"/>
</target>
</element>
<element>
<code value="tub004-0028"/>
<display value="Levofloxacin"/>
<target>
<code value="20629-2"/>
<display value="Levofloxacin [Susceptibility]"/>
<relationship value="equivalent"/>
</target>
</element>
<element>
<code value="tub004-0029"/>
<display value="Amikacin"/>
<target>
<code value="18860-7"/>
<display value="Amikacin [Susceptibility]"/>
<relationship value="equivalent"/>
</target>
</element>
<element>
<code value="tub004-0030"/>
<display value="Kanamycin"/>
<target>
<code value="18935-7"/>
<display value="Kanamycin [Susceptibility]"/>
<relationship value="equivalent"/>
</target>
</element>
</group>
</ConceptMap>